Short to Long Effects of Whole Body Cryostimulation on Insulin Sensitivity Among Overweight

May 7, 2021 updated by: Robert Olek, Gdansk University of Physical Education and Sport

Short to Long Effects of Whole Body Cryostimulation on Insulin Sensitivity Among Overweight: Translational Controlled Trial Investigating Coldness and Training Effects on Endocrine Regulation on Energy Metabolism

Therapeutic effectiveness of coldness in relieving pain and reducing inflammation has been known for many years now. Over that time, various coldness therapies have gained in popularity, including winter swimming, snow baths or whole body cryostimulation (WBC) . Recent researches have shown positive effects of WBC on metabolic profile, low-to-moderate chronic inflammation and related diseases (e.g., obesity). WBC could be, thus, intended as an adjuvant method in the treatment of dysmetabolic conditions, such as overweight or obesity. WBC is a cheap easily accessible practice, with a few well-defined contraindications and limited non severe possible adverse events, if performed in specialized centres. At the same time, in sport science appears data, which indicated on inhibition of adaptive changes induced by regular training.

The primary aim is to define, through a randomized controlled approach, the relative effectiveness of up to 20 consecutive sessions of either WBC, high-intensity intermittent training (HIIT), or their combination (WBC and HIIT) in improving the metabolic status of overweight and obese subjects. The effects will be assessed, at different time-points, in terms of insulin sensitivity and modification in the profile of hormones regulating the energy metabolism (adipokines, myokines, bone-derived hormones) and the inter-organ cross-talk.

Study Overview

Detailed Description

Secondary aims are:

  1. To assess the influence of WBC and HIIT on insulin sensitivity and establish the role of myokines (irisin and IL-6) in this regulation. To find the answer for the question if the rise of mentioned myokines cause a decrease of authophagy protein HMGB1.
  2. To characterize potential effectiveness of these intervention protocols on bone and energy metabolisms by stimulating in vitro cultured normal human osteoblastic primary cells and β-pancreatic cells with sera obtained from patients at different time points during treatment.
  3. To establish, which procedure is most effective at improving insulin sensitivity: training or training supported with WBC treatment, which factors modify this response (body composition or physical capacity of subjects)
  4. To establish if training supported with WBC treatment impairs adaptive changes of trained subjects
  5. To determine the potential beneficial effects of the intervention protocols on the metabolic homeostasis, and assess how long these changes are maintained over a period of four weeks or three months.

Study Type

Interventional

Enrollment (Anticipated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pomorskie
      • Sopot, Pomorskie, Poland, 81-735
        • Ziemann Ewa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • obesity (BMI >30kg/m2),
  • age >18 years,
  • diagnosis of impaired glucose tolerance (IGT),
  • functional autonomy,
  • ability to discernment,
  • no WBC treatment within the previous year.

Exclusion Criteria:

  • using insulin or other chronic medications,
  • inflammatory/immune-mediated pathologies,
  • T2D,
  • liver or kidney disease,
  • cardiovascular diseases,
  • neuropathy, retinopathy,
  • neoplasia, as well as fragility fractures of bones,
  • traumatic fractures in the previous 2 years,
  • contraindications for WBC and exercise

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: whole body cryostimulation treatment
WBC will be performed at the Pomeranian Rheumatologic Centre in Sopot. The centre is equipped with an electric cryochamber Zimmer Medicine System, Cryochamber ELECPOL, located in a temperature- and humidity-controlled room. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
The WBC is apporved by National Ministry of Health. It uses cryochamber with low temperature -110 oC. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
Experimental: Connection WBC treatment and HIIT training
This group will perform HIIT protocol and WBC sessions . HIIT will be performed after 1h WBC.
WBC combination with Exercise HIIT according to Litlle protocol from 2011. This exercise protocol will be applied together with cryo-sessions
Active Comparator: Control Group
Control group who will be investigated (meanwhile at baseline and after the interventions)
This group willnot to change their daily habits . The measurements will be taken at baseline and at the end of the study
Experimental: HIIT training group
This group will perform only HIIT protocol without cryo-sessions
This group will do the training program without cold exposure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The assessment of pro- and anti-inflammatory proteins concentration in blood , in response to applied procedures.
Time Frame: one month

Proinflammatory:

HMGB1 ng/ml, CRP ng/ml TNFalpha pg/ml

Anti-inflammaotry:

Irisin ng/ml Adiponectin ng/ml Leptin ng/lm IL-10 pg/ml

one month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of insulin sensitivity and insulin resistance
Time Frame: one month

Measurement of fasting glucose and after oral glucose test concentration:

glucose mg/ml insulin ng/ml, calculating Matsuda and HOMA indicators based on glucose and insulin concentrations

one month

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Expresion of proteins induced by serum collected from our subjects
Time Frame: 3 months
Human osteoblasts and β-pancreatic cell line will be treated by serum, which comes from our participants
3 months
Body composition assessment
Time Frame: one month
assessment of weight [kg], skeletal muscle mass [kg], fat tissue [kg]
one month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ewa Ziemann, Professor, Poznań University of Physical Education

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 3, 2018

Primary Completion (Actual)

December 30, 2019

Study Completion (Anticipated)

December 30, 2021

Study Registration Dates

First Submitted

April 29, 2020

First Submitted That Met QC Criteria

May 1, 2020

First Posted (Actual)

May 6, 2020

Study Record Updates

Last Update Posted (Actual)

May 11, 2021

Last Update Submitted That Met QC Criteria

May 7, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overweight

Clinical Trials on whole body cryostimulation treatment

3
Subscribe